查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1858094

肉瘤藥物市場按藥物類別、適應症、給藥途徑、最終用戶和治療方式分類－2025-2032年全球預測

Sarcoma Drugs Market by Drug Class, Indication, Route Of Administration, End User, Treatment Modality - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，肉瘤治療市場將成長至 31.6 億美元，複合年成長率為 8.35%。

主要市場統計數據
基準年 2024 16.6億美元
預計年份：2025年 18億美元
預測年份：2032年 31.6億美元
複合年成長率 (%) 8.35%

將科學進展與不同疾病類型的臨床、監管和商業性現實相結合，為肉瘤藥物策略奠定了基礎。

肉瘤治療是腫瘤學領域最複雜、技術要求最高的領域之一，涵蓋罕見組織學類型、異質性分子促進因素和治療途徑，需要多學科協作。本執行摘要首先將肉瘤置於更廣泛的腫瘤學生態系統中進行闡述。在這個治療領域，分子標靶療法、免疫腫瘤治療方法和複雜的細胞毒性方案與基因組學和組織病理學的診斷進展相交織。圍繞臨床開發、監管策略和市場准入的決策必須考慮到異質性患者群體、不斷發展的生物標記範式以及不斷變化的支付方預期。

分子譜分析、適應性測試設計和監管務實主義的進步如何重塑肉瘤藥物研發路徑和商業策略

在科學、監管和商業性力量的共同推動下，肉瘤領域正經歷著一場變革性的轉變，相關人員對計畫優先順序的設定和資源的分配方式也隨之改變。在科學層面，基因組分析和單細胞技術的進步加速了標靶發現和患者分層，使得針對分子定義的隊列進行小規模、更有效率、信噪比更高的檢測成為可能。同時，細胞療法和免疫腫瘤聯合治療的成熟，正在拓展傳統細胞毒性療法以外的潛在治療途徑。這些進展正在改變檢測設計的基本原理，促進適應性方案和平台檢測的開發，縮短檢測週期，並提升對罕見亞型的認知。

美國關稅趨勢至2025年對肉瘤藥物商業化供應鏈韌性、籌資策略和價格談判的影響

美國關稅的累積效應（效應將持續到2025年）為參與肉瘤治療藥物研發和分銷的贊助商、製造商和醫療保健系統帶來了新的考量。影響原料藥、關鍵材料和某些醫療設備的關稅可能導致供應鏈成本上升，並促使企業重新評估籌資策略和生產佈局。為了減輕進口關稅的影響並維持可預測的生產前置作業時間，製造商通常會最佳化供應商網路、在原料藥採購方面建立冗餘機制，並加快對區域製造的投資。

一個多維度細分框架，將藥物類別、適應症、給藥途徑、最終用戶和治療方式連結起來，以輔助優先排序和營運規劃。

細分市場分析揭示了相關人員可以從多個角度確定投資優先順序並調整開發計劃。依藥物類別分類，抗血管新生療法、化療、荷爾蒙療法、免疫療法和標靶治療是主要類別；抗血管新生療法可分為血小板衍生生長因子（PDGF）抑制劑和血管內皮生長因子（VEGF）抑制劑；化療可分為烷化劑、細胞週期蛋白類藥物、抗代謝藥物和拓樸異構酶抑制劑；免疫療法可分為過繼性細胞療法、癌症疫苗、查核點抑制劑和細胞激素療法；標靶治療可分為CDK4/6抑制劑、mTOR抑制劑、PARP抑制劑和蛋白酪氨酸激酶抑制劑。每類藥物都有不同的臨床試驗設計、安全性監測需求、生產複雜性和支付價值提案，因此開發團隊需要根據適應症和預期治療方案選擇藥物。

關鍵區域監管差異、臨床能力和報銷現狀如何影響戰略部署計劃和證據生成優先事項。

區域動態對肉瘤治療藥物的臨床開發、監管策略和商業性實施有顯著影響。美洲地區擁有先進的診斷基礎設施、完善的臨床實驗室網路，以及要求提供清晰成本效益報告的支付方環境，這些因素共同使其成為註冊研究和早期商業上市的重點區域。放眼歐洲、中東和非洲，相關人員會發現監管管道多元、報銷體系各異，診斷能力也參差不齊。在這些地區取得成功通常需要模組化的准入策略，以彌補國家衛生技術評估流程和罕見疾病中心能力方面的不足。在亞太地區，癌症研究的快速投入、臨床試驗參與度的提高以及報銷體系的演變，既帶來了機遇，也帶來了挑戰，因此需要特別關注本地化生產、區域監管協調以及符合當地文化習慣的患者參與方式。

平衡創新與規模：跨國開發商、領先生技公司與合作夥伴關係模式在推動肉瘤藥物研發的策略優勢

肉瘤治療領域的競爭格局融合了成熟的跨國腫瘤公司的規模和研發能力，以及專業生物技術企業的敏捷性和對特定分子的專注。擁有強大研發能力的大型製藥企業具備豐富的研發經驗、全球監管經驗和整合的商業管道，能夠加速後期專案的上市。它們的優勢包括能夠承保大規模註冊項目並協商複雜的支付方協議。相較之下，規模較小的生物技術公司通常透過利基機制推動創新，快速迭代以生物標記為導向的策略，並為尋求補充其產品組合的大型公司創造高價值的合作機會。因此，策略聯盟、授權協議和聯合開發夥伴關係關係十分常見，這使得聯合策略得以實施，並實現了公司間專業生產和臨床技術的共享。

對於肉瘤計畫而言，開發人員和相關人員在臨床設計、供應彈性、支付方證據產生和夥伴關係管治方面需要採取切實可行的策略措施。

產業領導者應採取果斷行動，在管控商業和營運風險的同時，將科學前景轉化為持續的患者獲益。首先，透過將早期研發與明確的市場推廣假設結合，減少浪費性投資並加快與支付方的溝通。這些假設應明確目標組織、生物標記策略和理想的治療環境。其次，投資於模組化、適應性強的測試設計，以便在分子定義的隊列中進行假設檢驗，加快概念驗證的公佈，並保留免疫療法和標靶藥物聯合治療策略的選擇。第三，透過原料藥來源多元化、探索區域性生產夥伴關係關係以及檢驗依賴器械給藥途徑的應急計畫，建構具有韌性的供應鏈，以減輕關稅和物流中斷的影響。

結合專家訪談、二手證據三角驗證和情境分析等多種方法的穩健混合研究途徑，確保了研究結果具有可操作性和可複製性。

本研究整合了專家訪談、文獻回顧以及對臨床、監管和商業性訊號的結構化分析，旨在全面展現肉瘤治療領域的現況。一級資訊來源包括對腫瘤內科醫生、臨床檢驗醫師、監管專家和市場准入專家的訪談，以解讀臨床實踐模式和支付方預期所反映的科學和商業趨勢。二級資訊來源包括同行評審的臨床文獻、監管指南、會議論文集以及藥物研發技術文件，這些資料經過三角驗證，以檢驗研究結果並為新興治療方法提供背景資訊。

整合策略重點，將科學進步轉化為永續的臨床影響，並預測肉瘤領域在營運、監管和支付方面面臨的挑戰

最後，肉瘤治療領域展現出令人著迷的科學機會與實際複雜性的交織。分子表徵、免疫療法設計和聯合療法的進步正在拓展可行的治療策略，但成功與否取決於臨床開發、監管規劃和商業性化準備的嚴格協調。按藥物類別、適應症、給藥途徑、治療方式和最終用戶進行精準細分，將有助於集中資源並提高檢測效率。區域策略必須體現診斷能力、監管管道和支付方期望方面的差異，而面對關稅和地緣政治壓力，供應鏈的韌性也變得日益重要。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 標靶蛋白酪氨酸激酶抑制劑的進展改善了肉瘤患者的生存結果
  • 快速發展的基因組分析技術使得個人化肉瘤治療方案成為可能。
  • 將免疫療法和化療整合到晚期肉瘤藥物研發管線中。
  • 一種新型雙特異性抗體，針對兩種肉瘤抗原，目前正處於臨床前和臨床試驗階段。
  • 監管突破加速罕見軟組織肉瘤亞型孤兒藥的核准
  • 針對抗藥性肉瘤細胞通道的新一代mTOR抑制劑進入市場
  • 提高肉瘤藥物定價和報銷策略中真實世界證據的採納率

第6章美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：肉瘤藥物市場（依藥物類別分類）

  • 抗血管新生療法
    • PDGF抑制劑
    • VEGF抑制劑
  • 化療
    • 烷化劑
    • 細胞週期蛋白
    • 抗代謝物
    • 拓樸異構酶抑制劑
  • 荷爾蒙療法
  • 免疫療法
    • 過繼性細胞療法
    • 癌症疫苗
    • 查核點抑制劑
    • 細胞激素療法
  • 標靶治療
    • CDK4/6抑制劑
    • MTOR抑制劑
    • PARP抑制劑
    • 蛋白酪氨酸激酶抑制劑

第9章 肉瘤藥物市場（依適應症分類）

  • 骨癌
    • 軟骨肉瘤
    • 伊文氏肉瘤
    • 骨癌
  • 胃腸道基質腫瘤
  • 卡波西氏肉瘤
  • 軟組織肉瘤
    • 平滑肌肉瘤
    • 脂肪肉瘤
    • 橫紋肌肉瘤
    • 滑膜肉瘤

第10章 按給藥途徑分類的肉瘤藥物市場

  • 肌肉內注射
  • 靜脈
  • 口服
  • 皮下

第11章 按最終用戶分類的肉瘤藥物市場

  • 門診手術中心
  • 居家醫療
  • 醫院
  • 專科診所

第12章 肉瘤藥物市場依治療方式分類

  • 聯合治療
    • 化療+免疫療法
    • 化療合併標標靶治療
    • 免疫療法合併標標靶治療
  • 單藥治療

第13章 各地區肉瘤藥物市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 肉瘤藥物市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 各國肉瘤藥物市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Novartis AG
    • Bayer AG
    • Pfizer Inc.
    • Ipsen SA
    • Eisai Co., Ltd.
    • Eli Lilly and Company
    • Deciphera Pharmaceuticals, LLC
    • Blueprint Medicines Corporation
    • Epizyme, Inc.
    • Merck & Co., Inc.
Product Code: MRR-C002B1C996FA

The Sarcoma Drugs Market is projected to grow by USD 3.16 billion at a CAGR of 8.35% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 1.66 billion
Estimated Year [2025] USD 1.80 billion
Forecast Year [2032] USD 3.16 billion
CAGR (%) 8.35%

Setting the context for sarcoma therapeutics strategy by aligning scientific advances with clinical, regulatory and commercial realities across heterogeneous disease types

Sarcoma therapeutics represent one of oncology's most complex and technically demanding areas, spanning rare histologies, heterogeneous molecular drivers and treatment pathways that require multidisciplinary coordination. This executive summary opens by situating sarcoma within the broader oncology ecosystem: a therapeutic domain where targeted molecular approaches, immuno-oncology modalities and refined cytotoxic regimens intersect with diagnostic advances in genomics and histopathology. The practical consequences for developers and health system stakeholders are profound; decisions around clinical development, regulatory strategy and market access must incorporate heterogeneous patient populations, evolving biomarker frameworks and shifting payer expectations.

Clinical progress has been uneven by histologic subtype, but recent years have delivered a richer understanding of disease biology, enabling more precise interventions in previously intractable presentations. Consequently, stakeholders must balance long-standing standards of care with novel mechanisms that may offer incremental or transformational benefit depending on the indication. This introduction frames the remainder of the analysis by highlighting the interplay of scientific innovation, stakeholder incentives and operational constraints that shape strategic choices across drug class, indication, administration route and treatment modality. It also underscores the imperative for commercially minded teams to integrate cross-functional intelligence-clinical, regulatory, supply chain and reimbursement-to navigate a fast-moving therapeutic landscape effectively.

How advances in molecular profiling, adaptive trial design, and regulatory pragmatism are reshaping development pathways and commercial strategies in sarcoma therapeutics

The sarcoma landscape is undergoing transformative shifts driven by converging scientific, regulatory and commercial forces that are reshaping how stakeholders prioritize programs and allocate resources. At the scientific level, enhanced genomic profiling and single-cell technologies have accelerated target discovery and patient stratification, enabling smaller, more efficient trials with higher signal-to-noise for molecularly defined cohorts. Concurrently, the maturation of cell therapy and combination immuno-oncology strategies is expanding the set of plausible therapeutic pathways beyond traditional cytotoxic regimens. These advances are changing trial design fundamentals, encouraging adaptive protocols and platform trials that reduce timelines and improve learning across rare subtypes.

From a regulatory perspective, agencies are signaling greater willingness to engage on novel endpoints, accelerated approval pathways and conditional licensing for rare diseases, provided there is robust post-approval evidence generation. This regulatory pragmatism incentivizes earlier and clearer alignment between developers and regulators on surrogate endpoints, real-world evidence collection and risk mitigation strategies. Commercially, payers and procurement systems are increasingly demanding transparent value narratives and outcomes-based contracting for high-cost interventions, which favors developers who can demonstrate durable benefit and manageable safety profiles. Together, these shifts underscore a new operating model for sarcoma programs: rapid biomarker-enabled segmentation, flexible clinical proof-of-concept approaches, and integrated downstream planning for access and lifecycle management.

Implications of US tariff dynamics through 2025 for supply chain resilience, sourcing strategies, and pricing negotiations in sarcoma drug commercialization

The cumulative effect of United States tariff measures implemented through 2025 has introduced new considerations for sponsors, manufacturers and health systems engaged in sarcoma drug development and distribution. Tariffs affecting active pharmaceutical ingredients, critical raw materials and certain medical equipment can raise incremental costs along the supply chain, prompting reassessments of sourcing strategies and manufacturing footprints. In many cases, manufacturers respond by re-optimizing supplier networks, building redundancy into API sourcing and accelerating regional manufacturing investments to mitigate exposure to import levies and to preserve predictable production lead times.

Beyond direct cost impacts, tariffs influence commercial negotiation dynamics with payers and distributors. Where reimbursement is tightly constrained, even modest cost increases can alter pricing strategies and contract terms. Procurement teams may prioritize suppliers with localized supply chains to reduce tariff-related volatility, and developers may find added leverage in forming toll-manufacturing partnerships or licensing arrangements that localize production closer to end markets. Regulatory clearance processes and quality oversight remain paramount; any rapid manufacturing relocation must maintain compliance with Good Manufacturing Practice and ensure supply continuity for patients with few therapeutic alternatives. Ultimately, the tariff environment increases the strategic value of robust supply chain planning, scenario modeling and early engagement with procurement and manufacturing partners to safeguard access and preserve commercial viability.

A multidimensional segmentation framework linking drug classes, indications, administration routes, end users and treatment modalities to inform prioritization and operational planning

Segmentation analysis reveals multiple lenses through which stakeholders can prioritize investment and tailor development plans. When examining drug class, key categories include Antiangiogenic Therapy, Chemotherapy, Hormonal Therapy, Immunotherapy, and Targeted Therapy; Antiangiogenic Therapy subdivides into PDGF Inhibitors and VEGF Inhibitors, Chemotherapy further separates into Alkylating Agents, Anthracyclines, Antimetabolites, and Topoisomerase Inhibitors, Immunotherapy encompasses Adoptive Cell Therapy, Cancer Vaccines, Checkpoint Inhibitors, and Cytokine Therapy, and Targeted Therapy includes CDK4/6 Inhibitors, MTOR Inhibitors, PARP Inhibitors, and Tyrosine Kinase Inhibitors. Each drug-class grouping implies different clinical trial designs, safety monitoring needs, manufacturing complexity and payer value propositions, so development teams should align modality selection with the intended indication and expected line of therapy.

Indication-based segmentation distinguishes Bone Sarcoma, Gastrointestinal Stromal Tumors, Kaposi Sarcoma, and Soft Tissue Sarcoma; within Bone Sarcoma, clinicians and developers consider Chondrosarcoma, Ewing Sarcoma, and Osteosarcoma as distinct biological entities with differing therapeutic responsiveness, while Soft Tissue Sarcoma includes Leiomyosarcoma, Liposarcoma, Rhabdomyosarcoma, and Synovial Sarcoma, each demanding tailored clinical endpoints and histology-specific consideration. Route of administration segmentation covers Intramuscular, Intravenous, Oral, and Subcutaneous options, which shape patient adherence expectations, outpatient versus inpatient delivery models, and device or formulation development needs. End user segmentation identifies Ambulatory Surgical Centers, Home Care environments, Hospitals, and Specialty Clinics as primary delivery settings, influencing channel strategies, training requirements and reimbursement pathways. Treatment modality differentiation between Combination Therapy and Monotherapy, with Combination Therapy including Chemotherapy Plus Immunotherapy, Chemotherapy Plus Targeted, and Immunotherapy Plus Targeted approaches, drives decisions on clinical coordination, safety overlap management and commercial collaboration frameworks between co-developers. By integrating these segmentation axes, organizations can map development choices to operational constraints and market access realities, enabling prioritized investments where clinical need, biological plausibility and practicable deployment converge.

How regional regulatory diversity, clinical capacity and reimbursement realities across major geographies shape strategic rollout plans and evidence generation priorities

Regional dynamics materially influence clinical development, regulatory strategy and commercial execution across sarcoma therapeutics. In the Americas, the landscape is characterized by advanced diagnostic infrastructure, well-established clinical trial networks and a payer environment that demands clear cost-effectiveness narratives, which together make it a focal point for registrational studies and early commercial launches. Transitioning to Europe, Middle East & Africa, stakeholders encounter diverse regulatory pathways, heterogenous reimbursement systems and varying levels of diagnostic capability; success in this region often requires modular access strategies that address country-level HTA processes and capacity gaps in rare disease centers of excellence. In the Asia-Pacific region, rapid investment in oncology research, expanding clinical trial participation and evolving reimbursement frameworks create both opportunity and complexity, with particular attention needed on local manufacturing, regional regulatory harmonization and culturally appropriate patient engagement.

Across these geographic areas, clinical trial enrollment logistics, availability of specialized sarcoma centers, and regional variations in histologic prevalence all shape trial feasibility and post-approval adoption. Accordingly, successful programs adopt phased regional strategies that leverage early wins in capacity-dense markets while simultaneously investing in evidence generation, local stakeholder engagement and manufacturing adjustments to support broader rollout. This geographically nuanced approach helps ensure that clinical data, regulatory submissions and commercial readiness progress in parallel and that regional reimbursement barriers are anticipated and addressed proactively.

Balancing innovation and scale: the strategic advantages of multinational developers, nimble biotechs, and collaborative partnership models in advancing sarcoma therapies

The competitive landscape in sarcoma therapeutics blends the scale and development capacity of established multinational oncology firms with the agility and molecular focus of specialty biotechs. Large pharma players bring extensive development expertise, global regulatory experience, and integrated commercial channels that accelerate late-stage programs to market; their strengths include ability to underwrite expansive registrational programs and to negotiate complex payer arrangements. In contrast, smaller biotech companies often drive innovation in niche mechanisms, rapidly iterate on biomarker-directed strategies, and create high-value partnering opportunities for larger organizations seeking to complement their portfolios. Strategic alliances, licensing deals and co-development partnerships are therefore common, enabling combination strategies and cross-company access to specialized manufacturing or clinical expertise.

Investors and corporate development teams should track not only pipeline breadth but also platform capabilities, biomarker development resources, and manufacturing readiness. Companies with strong translational medicine functions and access to comprehensive patient registries and histology-specific networks are better positioned to execute small, high-impact trials. Additionally, firms that demonstrate operational excellence in cell therapy logistics, companion diagnostic co-development, or novel formulation delivery stand to differentiate in commercialization discussions with payers and providers. Ultimately, winning companies will combine scientific differentiation with pragmatic execution: robust clinical programs, validated companion diagnostics where appropriate, and credible commercialization blueprints that address the end-to-end patient journey.

Practical strategic imperatives for developers and stakeholders to align clinical design, supply resilience, payer evidence generation and partnership governance for sarcoma programs

Industry leaders should act decisively to translate scientific promise into durable patient benefit while managing commercial and operational risk. First, align early-stage development with a clear go-to-market hypothesis that defines target histologies, biomarker strategies and preferred care settings; this alignment reduces wasted investment and accelerates payer conversations. Second, invest in modular and adaptive trial designs that enable hypothesis testing across molecularly defined cohorts, accelerate proof-of-concept readouts and preserve optionality for combination strategies with immunotherapies or targeted agents. Third, build resilient supply chains by diversifying API sources, considering regional manufacturing partnerships, and validating contingency plans for device-dependent administration routes to mitigate tariffs and logistical disruptions.

In parallel, prioritize evidence generation that meets payer needs: integrate health economics endpoints and quality-of-life measures into pivotal development programs, and plan for real-world data collection that supports durability claims post-approval. Engage payers, providers and centers of excellence early to shape acceptable endpoints and to secure pathways for access. For companies pursuing combination strategies, establish clear co-development agreements that align incentives and responsibilities for safety monitoring, data sharing and commercialization. Finally, strengthen patient engagement and advocacy partnerships to streamline trial recruitment, enhance retention and incorporate patient-centric outcomes into product value narratives. These combined actions will improve the probability of regulatory success, accelerate market adoption and foster sustainable value capture.

A robust mixed-methods research approach combining primary expert elicitation, secondary evidence triangulation, and scenario-based analysis to ensure actionable and reproducible insights

This research synthesizes primary expert interviews, secondary literature review and structured analysis of clinical, regulatory and commercial signals to provide a comprehensive view of the sarcoma therapeutic landscape. Primary inputs included interviews with oncologists, clinical trial investigators, regulatory experts and market access professionals, ensuring that clinical practice patterns and payer expectations informed interpretation of scientific and operational trends. Secondary sources encompassed peer-reviewed clinical literature, regulatory guidances, conference proceedings and technical drug development resources; these materials were triangulated to validate insights and to contextualize emerging therapeutic modalities.

Analytical methods combined qualitative thematic analysis with cross-sectional mapping of segmentation axes to reveal where biological plausibility, clinical need and operational feasibility intersect. Scenario analysis was used to explore the implications of supply chain shocks and tariff pressures on manufacturing and pricing strategies, while comparative benchmarking illuminated differentiators among developer archetypes. Throughout, emphasis was placed on transparent assumptions, reproducible workflows, and clear traceability between cited evidence and strategic conclusions. The methodology supports replicable updates as new clinical data, regulatory decisions or commercial developments emerge, enabling stakeholders to refresh strategies in response to evolving evidence.

Synthesis of strategic priorities for translating scientific advances into sustainable clinical impact while anticipating operational, regulatory and payer challenges in sarcoma

In closing, the sarcoma therapeutics arena presents a compelling mix of scientific opportunity and practical complexity. Progress in molecular characterization, immunotherapy design and combination approaches has expanded the set of viable therapeutic strategies, but success depends on disciplined alignment of clinical development, regulatory planning and commercial preparation. Robust segmentation-across drug class, indication, route of administration, treatment modality and end user-enables focused resource allocation and more efficient trial execution. Regional strategies must reflect differences in diagnostic capacity, regulatory pathways and payer expectations, and supply chain resilience is increasingly important in the face of tariff and geopolitical pressures.

Organizations that integrate translational science with adaptive trial design, build strategic partnerships to close capability gaps, and engage payers and patients early will be best positioned to translate innovation into sustained clinical and commercial impact. Thoughtful investment in evidence that demonstrates real-world value and in operations that secure reliable supply will accelerate adoption and improve outcomes for patients living with these rare and often aggressive diseases. The path forward requires both scientific rigor and pragmatic execution, and the recommendations offered here provide a framework to convert insight into effective action.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Advancements in targeted tyrosine kinase inhibitors improving sarcoma survival outcomes
  • 5.2. Rapidly evolving genomic profiling techniques enabling personalized sarcoma drug regimens
  • 5.3. Integration of immunotherapy combinations with chemotherapy in advanced sarcoma treatment pipelines
  • 5.4. Emerging bispecific antibodies targeting dual sarcoma antigens in preclinical and clinical trials
  • 5.5. Regulatory breakthroughs accelerating orphan drug approvals for rare soft tissue sarcoma subtypes
  • 5.6. Market entry of next generation mTOR inhibitors targeting resistant sarcoma cell pathways
  • 5.7. Increasing adoption of real world evidence to inform sarcoma drug pricing and reimbursement strategies

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Sarcoma Drugs Market, by Drug Class

  • 8.1. Antiangiogenic Therapy
    • 8.1.1. PDGF Inhibitors
    • 8.1.2. VEGF Inhibitors
  • 8.2. Chemotherapy
    • 8.2.1. Alkylating Agents
    • 8.2.2. Anthracyclines
    • 8.2.3. Antimetabolites
    • 8.2.4. Topoisomerase Inhibitors
  • 8.3. Hormonal Therapy
  • 8.4. Immunotherapy
    • 8.4.1. Adoptive Cell Therapy
    • 8.4.2. Cancer Vaccines
    • 8.4.3. Checkpoint Inhibitors
    • 8.4.4. Cytokine Therapy
  • 8.5. Targeted Therapy
    • 8.5.1. CDK4/6 Inhibitors
    • 8.5.2. MTOR Inhibitors
    • 8.5.3. PARP Inhibitors
    • 8.5.4. Tyrosine Kinase Inhibitors

9. Sarcoma Drugs Market, by Indication

  • 9.1. Bone Sarcoma
    • 9.1.1. Chondrosarcoma
    • 9.1.2. Ewing Sarcoma
    • 9.1.3. Osteosarcoma
  • 9.2. Gastrointestinal Stromal Tumors
  • 9.3. Kaposi Sarcoma
  • 9.4. Soft Tissue Sarcoma
    • 9.4.1. Leiomyosarcoma
    • 9.4.2. Liposarcoma
    • 9.4.3. Rhabdomyosarcoma
    • 9.4.4. Synovial Sarcoma

10. Sarcoma Drugs Market, by Route Of Administration

  • 10.1. Intramuscular
  • 10.2. Intravenous
  • 10.3. Oral
  • 10.4. Subcutaneous

11. Sarcoma Drugs Market, by End User

  • 11.1. Ambulatory Surgical Centers
  • 11.2. Home Care
  • 11.3. Hospitals
  • 11.4. Specialty Clinics

12. Sarcoma Drugs Market, by Treatment Modality

  • 12.1. Combination Therapy
    • 12.1.1. Chemotherapy Plus Immunotherapy
    • 12.1.2. Chemotherapy Plus Targeted
    • 12.1.3. Immunotherapy Plus Targeted
  • 12.2. Monotherapy

13. Sarcoma Drugs Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Sarcoma Drugs Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Sarcoma Drugs Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Novartis AG
    • 16.3.2. Bayer AG
    • 16.3.3. Pfizer Inc.
    • 16.3.4. Ipsen S.A.
    • 16.3.5. Eisai Co., Ltd.
    • 16.3.6. Eli Lilly and Company
    • 16.3.7. Deciphera Pharmaceuticals, LLC
    • 16.3.8. Blueprint Medicines Corporation
    • 16.3.9. Epizyme, Inc.
    • 16.3.10. Merck & Co., Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL SARCOMA DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL SARCOMA DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL SARCOMA DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL SARCOMA DRUGS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL SARCOMA DRUGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL SARCOMA DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL SARCOMA DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL SARCOMA DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS SARCOMA DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA SARCOMA DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA SARCOMA DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA SARCOMA DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE SARCOMA DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST SARCOMA DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA SARCOMA DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC SARCOMA DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL SARCOMA DRUGS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN SARCOMA DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC SARCOMA DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION SARCOMA DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS SARCOMA DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 SARCOMA DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO SARCOMA DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL SARCOMA DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. SARCOMA DRUGS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. SARCOMA DRUGS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. SARCOMA DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL SARCOMA DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL SARCOMA DRUGS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL SARCOMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL SARCOMA DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ANTIANGIOGENIC THERAPY, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ANTIANGIOGENIC THERAPY, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ANTIANGIOGENIC THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ANTIANGIOGENIC THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ANTIANGIOGENIC THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ANTIANGIOGENIC THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ANTIANGIOGENIC THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ANTIANGIOGENIC THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL SARCOMA DRUGS MARKET SIZE, BY PDGF INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL SARCOMA DRUGS MARKET SIZE, BY PDGF INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL SARCOMA DRUGS MARKET SIZE, BY PDGF INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL SARCOMA DRUGS MARKET SIZE, BY PDGF INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL SARCOMA DRUGS MARKET SIZE, BY PDGF INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL SARCOMA DRUGS MARKET SIZE, BY PDGF INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL SARCOMA DRUGS MARKET SIZE, BY VEGF INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL SARCOMA DRUGS MARKET SIZE, BY VEGF INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL SARCOMA DRUGS MARKET SIZE, BY VEGF INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL SARCOMA DRUGS MARKET SIZE, BY VEGF INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL SARCOMA DRUGS MARKET SIZE, BY VEGF INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL SARCOMA DRUGS MARKET SIZE, BY VEGF INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ALKYLATING AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ALKYLATING AGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ALKYLATING AGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ALKYLATING AGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ALKYLATING AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ALKYLATING AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ANTHRACYCLINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ANTHRACYCLINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ANTHRACYCLINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ANTHRACYCLINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ANTHRACYCLINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ANTHRACYCLINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ANTIMETABOLITES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ANTIMETABOLITES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ANTIMETABOLITES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ANTIMETABOLITES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ANTIMETABOLITES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ANTIMETABOLITES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL SARCOMA DRUGS MARKET SIZE, BY TOPOISOMERASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL SARCOMA DRUGS MARKET SIZE, BY TOPOISOMERASE INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL SARCOMA DRUGS MARKET SIZE, BY TOPOISOMERASE INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL SARCOMA DRUGS MARKET SIZE, BY TOPOISOMERASE INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL SARCOMA DRUGS MARKET SIZE, BY TOPOISOMERASE INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL SARCOMA DRUGS MARKET SIZE, BY TOPOISOMERASE INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL SARCOMA DRUGS MARKET SIZE, BY HORMONAL THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL SARCOMA DRUGS MARKET SIZE, BY HORMONAL THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL SARCOMA DRUGS MARKET SIZE, BY HORMONAL THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL SARCOMA DRUGS MARKET SIZE, BY HORMONAL THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL SARCOMA DRUGS MARKET SIZE, BY HORMONAL THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL SARCOMA DRUGS MARKET SIZE, BY HORMONAL THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ADOPTIVE CELL THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ADOPTIVE CELL THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ADOPTIVE CELL THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ADOPTIVE CELL THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ADOPTIVE CELL THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ADOPTIVE CELL THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CANCER VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CANCER VACCINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CANCER VACCINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CANCER VACCINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CANCER VACCINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CANCER VACCINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CYTOKINE THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CYTOKINE THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CYTOKINE THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CYTOKINE THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CYTOKINE THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CYTOKINE THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL SARCOMA DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL SARCOMA DRUGS MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL SARCOMA DRUGS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL SARCOMA DRUGS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL SARCOMA DRUGS MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL SARCOMA DRUGS MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL SARCOMA DRUGS MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL SARCOMA DRUGS MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CDK4/6 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CDK4/6 INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CDK4/6 INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CDK4/6 INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CDK4/6 INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CDK4/6 INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL SARCOMA DRUGS MARKET SIZE, BY MTOR INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL SARCOMA DRUGS MARKET SIZE, BY MTOR INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL SARCOMA DRUGS MARKET SIZE, BY MTOR INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL SARCOMA DRUGS MARKET SIZE, BY MTOR INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL SARCOMA DRUGS MARKET SIZE, BY MTOR INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL SARCOMA DRUGS MARKET SIZE, BY MTOR INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL SARCOMA DRUGS MARKET SIZE, BY PARP INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL SARCOMA DRUGS MARKET SIZE, BY PARP INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL SARCOMA DRUGS MARKET SIZE, BY PARP INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL SARCOMA DRUGS MARKET SIZE, BY PARP INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL SARCOMA DRUGS MARKET SIZE, BY PARP INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL SARCOMA DRUGS MARKET SIZE, BY PARP INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL SARCOMA DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL SARCOMA DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL SARCOMA DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL SARCOMA DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL SARCOMA DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL SARCOMA DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL SARCOMA DRUGS MARKET SIZE, BY BONE SARCOMA, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL SARCOMA DRUGS MARKET SIZE, BY BONE SARCOMA, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL SARCOMA DRUGS MARKET SIZE, BY BONE SARCOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL SARCOMA DRUGS MARKET SIZE, BY BONE SARCOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL SARCOMA DRUGS MARKET SIZE, BY BONE SARCOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL SARCOMA DRUGS MARKET SIZE, BY BONE SARCOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL SARCOMA DRUGS MARKET SIZE, BY BONE SARCOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL SARCOMA DRUGS MARKET SIZE, BY BONE SARCOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CHONDROSARCOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CHONDROSARCOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CHONDROSARCOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CHONDROSARCOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CHONDROSARCOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CHONDROSARCOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL SARCOMA DRUGS MARKET SIZE, BY EWING SARCOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL SARCOMA DRUGS MARKET SIZE, BY EWING SARCOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL SARCOMA DRUGS MARKET SIZE, BY EWING SARCOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL SARCOMA DRUGS MARKET SIZE, BY EWING SARCOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL SARCOMA DRUGS MARKET SIZE, BY EWING SARCOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL SARCOMA DRUGS MARKET SIZE, BY EWING SARCOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL SARCOMA DRUGS MARKET SIZE, BY OSTEOSARCOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL SARCOMA DRUGS MARKET SIZE, BY OSTEOSARCOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL SARCOMA DRUGS MARKET SIZE, BY OSTEOSARCOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL SARCOMA DRUGS MARKET SIZE, BY OSTEOSARCOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL SARCOMA DRUGS MARKET SIZE, BY OSTEOSARCOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL SARCOMA DRUGS MARKET SIZE, BY OSTEOSARCOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL SARCOMA DRUGS MARKET SIZE, BY GASTROINTESTINAL STROMAL TUMORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL SARCOMA DRUGS MARKET SIZE, BY GASTROINTESTINAL STROMAL TUMORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL SARCOMA DRUGS MARKET SIZE, BY GASTROINTESTINAL STROMAL TUMORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL SARCOMA DRUGS MARKET SIZE, BY GASTROINTESTINAL STROMAL TUMORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL SARCOMA DRUGS MARKET SIZE, BY GASTROINTESTINAL STROMAL TUMORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL SARCOMA DRUGS MARKET SIZE, BY GASTROINTESTINAL STROMAL TUMORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL SARCOMA DRUGS MARKET SIZE, BY KAPOSI SARCOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL SARCOMA DRUGS MARKET SIZE, BY KAPOSI SARCOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL SARCOMA DRUGS MARKET SIZE, BY KAPOSI SARCOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL SARCOMA DRUGS MARKET SIZE, BY KAPOSI SARCOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL SARCOMA DRUGS MARKET SIZE, BY KAPOSI SARCOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL SARCOMA DRUGS MARKET SIZE, BY KAPOSI SARCOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL SARCOMA DRUGS MARKET SIZE, BY SOFT TISSUE SARCOMA, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL SARCOMA DRUGS MARKET SIZE, BY SOFT TISSUE SARCOMA, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL SARCOMA DRUGS MARKET SIZE, BY SOFT TISSUE SARCOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL SARCOMA DRUGS MARKET SIZE, BY SOFT TISSUE SARCOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL SARCOMA DRUGS MARKET SIZE, BY SOFT TISSUE SARCOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL SARCOMA DRUGS MARKET SIZE, BY SOFT TISSUE SARCOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL SARCOMA DRUGS MARKET SIZE, BY SOFT TISSUE SARCOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL SARCOMA DRUGS MARKET SIZE, BY SOFT TISSUE SARCOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL SARCOMA DRUGS MARKET SIZE, BY LEIOMYOSARCOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL SARCOMA DRUGS MARKET SIZE, BY LEIOMYOSARCOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL SARCOMA DRUGS MARKET SIZE, BY LEIOMYOSARCOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL SARCOMA DRUGS MARKET SIZE, BY LEIOMYOSARCOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL SARCOMA DRUGS MARKET SIZE, BY LEIOMYOSARCOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL SARCOMA DRUGS MARKET SIZE, BY LEIOMYOSARCOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL SARCOMA DRUGS MARKET SIZE, BY LIPOSARCOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL SARCOMA DRUGS MARKET SIZE, BY LIPOSARCOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL SARCOMA DRUGS MARKET SIZE, BY LIPOSARCOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL SARCOMA DRUGS MARKET SIZE, BY LIPOSARCOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL SARCOMA DRUGS MARKET SIZE, BY LIPOSARCOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL SARCOMA DRUGS MARKET SIZE, BY LIPOSARCOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL SARCOMA DRUGS MARKET SIZE, BY RHABDOMYOSARCOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL SARCOMA DRUGS MARKET SIZE, BY RHABDOMYOSARCOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL SARCOMA DRUGS MARKET SIZE, BY RHABDOMYOSARCOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL SARCOMA DRUGS MARKET SIZE, BY RHABDOMYOSARCOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL SARCOMA DRUGS MARKET SIZE, BY RHABDOMYOSARCOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL SARCOMA DRUGS MARKET SIZE, BY RHABDOMYOSARCOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL SARCOMA DRUGS MARKET SIZE, BY SYNOVIAL SARCOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL SARCOMA DRUGS MARKET SIZE, BY SYNOVIAL SARCOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL SARCOMA DRUGS MARKET SIZE, BY SYNOVIAL SARCOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL SARCOMA DRUGS MARKET SIZE, BY SYNOVIAL SARCOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL SARCOMA DRUGS MARKET SIZE, BY SYNOVIAL SARCOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL SARCOMA DRUGS MARKET SIZE, BY SYNOVIAL SARCOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL SARCOMA DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL SARCOMA DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL SARCOMA DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL SARCOMA DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL SARCOMA DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL SARCOMA DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL SARCOMA DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL SARCOMA DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL SARCOMA DRUGS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL SARCOMA DRUGS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL SARCOMA DRUGS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL SARCOMA DRUGS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL SARCOMA DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL SARCOMA DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL SARCOMA DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL SARCOMA DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL SARCOMA DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL SARCOMA DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL SARCOMA DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL SARCOMA DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL SARCOMA DRUGS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL SARCOMA DRUGS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL SARCOMA DRUGS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL SARCOMA DRUGS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL SARCOMA DRUGS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL SARCOMA DRUGS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL SARCOMA DRUGS MARKET SIZE, BY HOME CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL SARCOMA DRUGS MARKET SIZE, BY HOME CARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL SARCOMA DRUGS MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL SARCOMA DRUGS MARKET SIZE, BY HOME CARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL SARCOMA DRUGS MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL SARCOMA DRUGS MARKET SIZE, BY HOME CARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL SARCOMA DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL SARCOMA DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL SARCOMA DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL SARCOMA DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL SARCOMA DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL SARCOMA DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL SARCOMA DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL SARCOMA DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL SARCOMA DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL SARCOMA DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL SARCOMA DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL SARCOMA DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL SARCOMA DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL SARCOMA DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL SARCOMA DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL SARCOMA DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL SARCOMA DRUGS MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL SARCOMA DRUGS MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL SARCOMA DRUGS MARKET SIZE, BY COMBINATION THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL SARCOMA DRUGS MARKET SIZE, BY COMBINATION THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL SARCOMA DRUGS MARKET SIZE, BY COMBINATION THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL SARCOMA DRUGS MARKET SIZE, BY COMBINATION THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY PLUS IMMUNOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY PLUS IMMUNOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY PLUS IMMUNOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY PLUS IMMUNOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY PLUS IMMUNOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY PLUS IMMUNOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY PLUS TARGETED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY PLUS TARGETED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY PLUS TARGETED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY PLUS TARGETED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY PLUS TARGETED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 274. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY PLUS TARGETED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY PLUS TARGETED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY PLUS TARGETED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 277. GLOBAL SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY PLUS TARGETED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 278. GLOBAL SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY PLUS TARGETED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 279. GLOBAL SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY PLUS TARGETED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 280. GLOBAL SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY PLUS TARGETED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 281. GLOBAL SARCOMA DRUGS MARKET SIZE, BY MONOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 282. GLOBAL SARCOMA DRUGS MARKET SIZE, BY MONOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 283. GLOBAL SARCOMA DRUGS MARKET SIZE, BY MONOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 284. GLOBAL SARCOMA DRUGS MARKET SIZE, BY MONOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 285. GLOBAL SARCOMA DRUGS MARKET SIZE, BY MONOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 286. GLOBAL SARCOMA DRUGS MARKET SIZE, BY MONOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 287. GLOBAL SARCOMA DRUGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 288. GLOBAL SARCOMA DRUGS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 289. AMERICAS SARCOMA DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 290. AMERICAS SARCOMA DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 291. AMERICAS SARCOMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 292. AMERICAS SARCOMA DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 293. AMERICAS SARCOMA DRUGS MARKET SIZE, BY ANTIANGIOGENIC THERAPY, 2018-2024 (USD MILLION)
  • TABLE 294. AMERICAS SARCOMA DRUGS MARKET SIZE, BY ANTIANGIOGENIC THERAPY, 2025-2032 (USD MILLION)
  • TABLE 295. AMERICAS SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 296. AMERICAS SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 297. AMERICAS SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 298. AMERICAS SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 299. AMERICAS SARCOMA DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 300. AMERICAS SARCOMA DRUGS MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
  • TABLE 301. AMERICAS SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 302. AMERICAS SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 303. AMERICAS SARCOMA DRUGS MARKET SIZE, BY BONE SARCOMA, 2018-2024 (USD MILLION)
  • TABLE 304. AMERICAS SARCOMA DRUGS MARKET SIZE, BY BONE SARCOMA, 2025-2032 (USD MILLION)
  • TABLE 305. AMERICAS SARCOMA DRUGS MARKET SIZE, BY SOFT TISSUE SARCOMA, 2018-2024 (USD MILLION)
  • TABLE 306. AMERICAS SARCOMA DRUGS MARKET SIZE, BY SOFT TISSUE SARCOMA, 2025-2032 (USD MILLION)
  • TABLE 307. AMERICAS SARCOMA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 308. AMERICAS SARCOMA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 309. AMERICAS SARCOMA DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 310. AMERICAS SARCOMA DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 311. AMERICAS SARCOMA DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
  • TABLE 312. AMERICAS SARCOMA DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2025-2032 (USD MILLION)
  • TABLE 313. AMERICAS SARCOMA DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
  • TABLE 314. AMERICAS SARCOMA DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2025-2032 (USD MILLION)
  • TABLE 315. NORTH AMERICA SARCOMA DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 316. NORTH AMERICA SARCOMA DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 317. NORTH AMERICA SARCOMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 318. NORTH AMERICA SARCOMA DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 319. NORTH AMERICA SARCOMA DRUGS MARKET SIZE, BY ANTIANGIOGENIC THERAPY, 2018-2024 (USD MILLION)
  • TABLE 320. NORTH AMERICA SARCOMA DRUGS MARKET SIZE, BY ANTIANGIOGENIC THERAPY, 2025-2032 (USD MILLION)
  • TABLE 321. NORTH AMERICA SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 322. NORTH AMERICA SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 323. NORTH AMERICA SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 324. NORTH AMERICA SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 325. NORTH AMERICA SARCOMA DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 326. NORTH AMERICA SARCOMA DRUGS MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
  • TABLE 327. NORTH AMERICA SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 328. NORTH AMERICA SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 329. NORTH AMERICA SARCOMA DRUGS MARKET SIZE, BY BONE SARCOMA, 2018-2024 (USD MILLION)
  • TABLE 330. NORTH AMERICA SARCOMA DRUGS MARKET SIZE, BY BONE SARCOMA, 2025-2032 (USD MILLION)
  • TABLE 331. NORTH AMERICA SARCOMA DRUGS MARKET SIZE, BY SOFT TISSUE SARCOMA, 2018-2024 (USD MILLION)
  • TABLE 332. NORTH AMERICA SARCOMA DRUGS MARKET SIZE, BY SOFT TISSUE SARCOMA, 2025-2032 (USD MILLION)
  • TABLE 333. NORTH AMERICA SARCOMA DRUGS MARKET SIZE, BY R